Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial

Fig. 3

Pharmacokinetic data following single oral dose zibotentan for patients in ZEBRA 2B. A Zibotentan blood plasma levels for all patients after 2.5 mg single oral dose. The upper panel shows the concentration of zibotentan (ng/ml) at 6 after a single oral dose of 2.5 mg zibotentan in six patients on haemodialysis. The final samples were taken pre- and post-dialysis to explore clearance of zibotentan. B Zibotentan blood plasma levels for patients receiving 5 mg single oral dose. Concentration of zibotentan (ng/ml) for the two patients that were re-dosed with 5 mg oral zibotentan is plotted against time with the final two samples being pre- and post-haemodialysis

Back to article page